Exelixis (EXEL) Quick Ratio: History & Chart

Exelixis, Inc.(EXEL)

Biotechnology · Alameda, CA

$58.33-0.52 (-0.88%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About Exelixis, Inc.

Exelixis, Inc. operates as a biotechnology firm dedicated to combating cancer, primarily focusing on the identification, advancement, and marketing of novel oncological treatments within the United States. Its portfolio of commercially available therapeutics includes CABOMETYX tablets, prescribed for individuals with advanced renal cell carcinoma who have previously undergone anti-angiogenic treatment, and COMETRIQ capsules, utilized for managing progressive and metastatic medullary thyroid cancer. Both CABOMETYX and COMETRIQ originate from cabozantinib, a compound that inhibits several tyrosine kinases such as MET, AXL, RET, and VEGF receptors. Additionally, Exelixis offers COTELLIC, an MEK inhibitor employed in combination therapies for advanced melanoma, and MINNEBRO, an orally administered, non-steroidal selective mineralocorticoid receptor blocker, approved for hypertension treatment in Japan. The company's developmental pipeline features several promising candidates, such as XL092, an oral tyrosine kinase inhibitor designed to target VEGF receptors, MET, AXL, MER, and other kinases crucial for cancer proliferation; XB002, an antibody-drug conjugate containing a human monoclonal antibody against tissue factor (TF), intended for advanced solid tumors and non-Hodgkin's lymphoma; and XL102, an orally available cyclin-dependent kinase 7 (CDK7) inhibitor being developed for advanced or metastatic solid tumors. Exelixis, Inc. maintains extensive research partnerships and licensing arrangements with numerous pharmaceutical and biotechnology entities, including Ipsen Pharma SAS, Takeda Pharmaceutical Company Ltd., F. Hoffmann-La Roche Ltd., Redwood Bioscience, Inc., R.P. Scherer Technologies, LLC, Catalent Pharma Solutions, Inc., NBE Therapeutics AG, Aurigene Discovery Technologies Limited, Iconic Therapeutics, Inc., Invenra, Inc., StemSynergy Therapeutics, Inc., Genentech, Inc., Bristol-Myers Squibb Company, and Daiichi Sankyo Company, Limited. Established in 1994, the company originally operated as Exelixis Pharmaceuticals, Inc. before rebranding to Exelixis, Inc. in February 2000. Its corporate headquarters are located in Alameda, California.

Alameda, CA

1,077 employees

www.exelixis.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Michael Morrissey

View full financials

EXEL Quick Ratio (Acid-Test) Metrics

QUICK RATIO (ACID-TEST)

3.38

QUICK RATIO (ACID-TEST) AVG TTM

3.44

QUICK RATIO (ACID-TEST) AVG 3Y

3.50

QUICK RATIO (ACID-TEST) AVG 5Y

4.34

QUICK RATIO (ACID-TEST) AVG 10Y

5.24

QUICK RATIO (ACID-TEST) AVG 15Y

4.52

QUICK RATIO (ACID-TEST) AVG 20Y

3.78

CURRENT VS TTM AVG

-1.78%

CURRENT VS 3Y AVG

-3.66%

CURRENT VS 5Y AVG

-22.23%

CURRENT VS 10Y AVG

-35.62%

CURRENT VS 15Y AVG

-25.30%

CURRENT VS 20Y AVG

-10.72%

SECTOR MEDIAN · HEALTHCARE

3.35

median of 870 covered companies

CURRENT VS SECTOR MEDIAN

+0.64%

vs the sector median at left

NAME	MARKET CAP	QUICK RATIO (ACID-TEST)	TTM	3Y	5Y
Exelixis, Inc. (EXEL)	$14.66B	3.38	3.44	3.50	4.34
Charles River Laboratories International, Inc. (CRL)vs ›	$14.69B	1.04	1.07	1.10	1.11
Neurocrine Biosciences, Inc. (NBIX)vs ›	$14.63B	1.75	3.29	2.91	3.46
Jazz Pharmaceuticals plc (JAZZ)vs ›	$14.54B	1.58	2.83	2.38	2.61
Solventum Corporation (SOLV)vs ›	$15.07B	0.74	0.86	0.93	0.94
Ascendis Pharma A/S (ASND)vs ›	$14.04B	2.32	0.80	0.84	4.11
Summit Therapeutics Inc. (SMMT)vs ›	$13.81B	6.96	10.01	11.56	9.08
BridgeBio Pharma, Inc. (BBIO)vs ›	$13.11B	1.17	3.59	3.76	4.72
Halozyme Therapeutics, Inc. (HALO)vs ›	$13.01B	2.31	5.22	5.21	4.91
Corcept Therapeutics Incorporated (CORT)vs ›	$12.93B	2.77	3.05	4.30	5.45

NAME

MARKET CAP

QUICK RATIO (ACID-TEST)

TTM

Exelixis, Inc. (EXEL)

$14.66B

3.38

3.44

3.50

4.34

Charles River Laboratories International, Inc. (CRL)vs ›

$14.69B

1.04

1.07

1.10

1.11

Neurocrine Biosciences, Inc. (NBIX)vs ›

$14.63B

1.75

3.29

2.91

3.46

Jazz Pharmaceuticals plc (JAZZ)vs ›

$14.54B

1.58

2.83

2.38

2.61

Solventum Corporation (SOLV)vs ›

$15.07B

0.74

0.86

0.93

0.94

Ascendis Pharma A/S (ASND)vs ›

$14.04B

2.32

0.80

0.84

4.11

Summit Therapeutics Inc. (SMMT)vs ›

$13.81B

6.96

10.01

11.56

9.08

BridgeBio Pharma, Inc. (BBIO)vs ›

$13.11B

1.17

3.59

3.76

4.72

Halozyme Therapeutics, Inc. (HALO)vs ›

$13.01B

2.31

5.22

5.21

4.91

Corcept Therapeutics Incorporated (CORT)vs ›

$12.93B

2.77

3.05

4.30

5.45

Quick Ratio (Acid-Test) FAQ

What is the quick ratio (acid-test) for Exelixis, Inc. (EXEL)?

The quick ratio (acid-test) for EXEL stock is 3.38.

Is Exelixis, Inc.'s quick ratio (acid-test) high or low?

The quick ratio (acid-test) of 3.38 is 22% below its 5-year average of 4.34, near the low end of its 5-year range (3.19–6.28).

What is the TTM average quick ratio (acid-test) for Exelixis, Inc. (EXEL)?

The TTM average quick ratio (acid-test) for EXEL stock is 3.44.

What is the 3Y average quick ratio (acid-test) for Exelixis, Inc. (EXEL)?

The 3Y average quick ratio (acid-test) for EXEL stock is 3.50.

What is the 5Y average quick ratio (acid-test) for Exelixis, Inc. (EXEL)?

The 5Y average quick ratio (acid-test) for EXEL stock is 4.34.

What is the 10Y average quick ratio (acid-test) for Exelixis, Inc. (EXEL)?

The 10Y average quick ratio (acid-test) for EXEL stock is 5.24.

What is the 15Y average quick ratio (acid-test) for Exelixis, Inc. (EXEL)?

The 15Y average quick ratio (acid-test) for EXEL stock is 4.52.

What is the 20Y average quick ratio (acid-test) for Exelixis, Inc. (EXEL)?

The 20Y average quick ratio (acid-test) for EXEL stock is 3.78.

DATE	QUICK RATIO (ACID-TEST)
2026-07-03	3.38
2026-04-03	3.19
2026-01-02	3.50
2025-10-03	3.68
2025-07-04	3.44
2025-04-04	3.44
2024-12-31	3.58
2024-09-27	3.88
2024-06-28	4.21
2024-03-29	3.41
2023-12-31	3.30
2023-09-29	3.76
2023-06-30	4.60
2023-03-31	4.91
2022-12-31	4.89
2022-09-30	6.01
2022-07-01	5.97
2022-04-01	6.28
2021-12-31	5.35
2021-10-01	6.06
2021-07-02	6.14
2021-04-02	6.61
2020-12-31	6.96
2020-10-02	6.90
2020-07-03	9.66
2020-04-03	7.98
2019-12-31	6.99
2019-09-27	6.80
2019-06-28	8.53
2019-03-29	7.48
2018-12-31	8.41
2018-09-28	8.54
2018-06-29	6.78
2018-03-30	6.58
2017-12-31	4.15
2017-09-29	4.27
2017-06-30	4.06
2017-03-31	2.30
2016-12-31	1.73
2016-09-30	2.07
2016-07-01	1.82
2016-04-01	3.33
2015-12-31	3.37
2015-10-02	3.67
2015-07-03	1.48
2015-04-03	2.09
2014-12-31	0.96
2014-09-26	1.25
2014-06-27	1.49
2014-03-28	4.16
2013-12-31	3.00
2013-09-27	3.91
2013-06-28	5.02
2013-03-29	5.66
2012-12-31	5.29
2012-09-30	5.78
2012-06-29	2.37
2012-03-30	2.86
2011-12-31	2.48
2011-09-30	1.47
2011-07-01	1.47
2011-04-01	1.64
2010-12-31	0.92
2010-10-01	0.94
2010-07-02	1.06
2010-04-02	0.84
2009-12-31	1.11
2009-10-02	1.43
2009-07-03	1.16
2009-04-03	1.30
2008-12-31	1.43
2008-09-26	1.14
2008-06-27	1.46
2008-03-28	2.06
2007-12-31	2.37
2007-09-28	2.36
2007-06-29	2.00
2007-03-30	2.70
2006-12-31	2.30
2006-09-30	1.64
2006-06-30	2.11
2006-03-31	1.72
2005-12-31	1.88
2005-09-30	2.34
2005-06-30	2.09
2005-03-31	2.09
2004-12-31	2.57
2004-09-30	3.38
2004-06-30	4.20
2004-03-31	4.38
2003-12-31	4.51
2003-09-30	4.66
2003-06-30	4.64
2003-03-31	3.64
2002-12-31	4.45
2002-09-30	4.99

DATE

QUICK RATIO (ACID-TEST)

2026-07-03

3.38

2026-04-03

3.19

2026-01-02

3.50

2025-10-03

3.68

2025-07-04

3.44

2025-04-04

3.44

2024-12-31

3.58

2024-09-27

3.88

2024-06-28

4.21

2024-03-29

3.41

2023-12-31

3.30

2023-09-29

3.76

2023-06-30

4.60

2023-03-31

4.91

2022-12-31

4.89

2022-09-30

6.01

2022-07-01

5.97

2022-04-01

6.28

2021-12-31

5.35

2021-10-01

6.06

2021-07-02

6.14

2021-04-02

6.61

2020-12-31

6.96

2020-10-02

6.90

2020-07-03

9.66

2020-04-03

7.98

2019-12-31

6.99

2019-09-27

6.80

2019-06-28

8.53

2019-03-29

7.48

2018-12-31

8.41

2018-09-28

8.54

2018-06-29

6.78

2018-03-30

6.58

2017-12-31

4.15

2017-09-29

4.27

2017-06-30

4.06

2017-03-31

2.30

2016-12-31

1.73

2016-09-30

2.07

2016-07-01

1.82

2016-04-01

3.33

2015-12-31

3.37

2015-10-02

3.67

2015-07-03

1.48

2015-04-03

2.09

2014-12-31

0.96

2014-09-26

1.25

2014-06-27

1.49

2014-03-28

4.16

2013-12-31

3.00

2013-09-27

3.91

2013-06-28

5.02

2013-03-29

5.66

2012-12-31

5.29

2012-09-30

5.78

2012-06-29

2.37

2012-03-30

2.86

2011-12-31

2.48

2011-09-30

1.47

2011-07-01

1.47

2011-04-01

1.64

2010-12-31

0.92

2010-10-01

0.94

2010-07-02

1.06

2010-04-02

0.84

2009-12-31

1.11

2009-10-02

1.43

2009-07-03

1.16

2009-04-03

1.30

2008-12-31

1.43

2008-09-26

1.14

2008-06-27

1.46

2008-03-28

2.06

2007-12-31

2.37

2007-09-28

2.36

2007-06-29

2.00

2007-03-30

2.70

2006-12-31

2.30

2006-09-30

1.64

2006-06-30

2.11

2006-03-31

1.72

2005-12-31

1.88

2005-09-30

2.34

2005-06-30

2.09

2005-03-31

2.09

2004-12-31

2.57

2004-09-30

3.38

2004-06-30

4.20

2004-03-31

4.38

2003-12-31

4.51

2003-09-30

4.66

2003-06-30

4.64

2003-03-31

3.64

2002-12-31

4.45

2002-09-30

4.99

Quick Ratio (Acid-Test): 3.38

EXEL Quick Ratio

EXEL Average Quick Ratio (Acid-Test) Chart

EXEL Current vs Average Quick Ratio (Acid-Test) Chart

EXEL Quick Ratio (Acid-Test) Metrics

EXEL Competitors' Quick Ratio (Acid-Test)

Liquidity Comparison

Quick Ratio (Acid-Test) Formula & Definition

Quick Ratio (Acid-Test) FAQ

EXEL Quick Ratio (Acid-Test) History

Related Metrics